Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

calaspargase pegol

(kal-AS-par-jays PEH-gol)
A drug used with other drugs to treat acute lymphoblastic leukemia in children and young adults aged 1 month to 21 years. It is also being studied in the treatment of other types of cancer. Calaspargase pegol is made up of the enzyme L-asparaginase that is linked to a substance called SC-PEG, which makes the drug stay in the body longer. L-asparaginase comes from the bacterium E. coli and breaks down the amino acid asparagine. This may stop the growth of cancer cells that need asparagine to grow. Calaspargase pegol is a type of protein synthesis inhibitor. Also called Asparlas, EZN-2285, and SC-PEG E. coli L-asparaginase.
More Information
Search NCI's Dictionary of Cancer Terms